Clinical trials: Neoplasms, Germ Cell and Embryonal
Melanoma
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
Effective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective.
- Trial name
- NCT02656706
- Testing
- Ipilumumab, Nivolumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Brown University
Advanced Solid Tumors
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy…
- Trial name
- NCT05599984
- Testing
- ABBV-706, Cisplatin, Budigalimab
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 288 people
- Sponsor
- AbbVie
Gastro-entero-pancreatic Carcinoma, Esophageal Neuroendocrine Carcinoma
Octreotide LAR as Maintenance Treatment for Patients With NEC
This is phase II study on the efficacy of octreotide lar as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas.
- Trial name
- NCT02409849
- Testing
- Octreotide lar
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Peking University
Glioblastoma Multiforme
Response Assessment During MR-guided Radiation Therapy for Glioblastoma
The study seeks to assess the response of glioblastoma multiforme to treatment using weekly low field (0.35 T) MR-images of the brain at a MRIdian® linac system during standard radiotherapy at the same system.
- Trial name
- MARGA (NCT05565326)
- Testing
- Low field (0.35 T) MR-images of the brain at a MRIdian® linac system
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Malignant Melanoma
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer…
- Trial name
- NCT01288963
- Testing
- IL-2
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Beth Israel Deaconess Medical Center
Melanoma (Skin)
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III…
- Trial name
- NCT00002763
- Testing
- recombinant interferon alfa
- Where
- 86 sites in Austria, Belgium and 19 more
- Volunteers
- 1,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Glioma, Glioblastoma Multiforme
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.
- Trial name
- NCT02590263
- Testing
- Whole Brain Radiation, Temozolomide, ABT-414
- Where
- 22 sites in Japan
- Volunteers
- 53 people
- Sponsor
- AbbVie
Melanoma
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy.
- Trial name
- OCEANMIST (NCT05260684)
- Testing
- Encorafenib, Binimetinib, Vemurafenib
- Where
- United States
- Volunteers
- 716 people
- Sponsor
- Pfizer
Medullary Thyroid Cancer
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
The aim of the trial is to study a radiating diagnosis agent used in post surgery when the biological assessment highlighted a residual disease.
- Trial name
- CMTpostopFDOPA (NCT02856347)
- Testing
- 18F-DOPA
- Where
- 5 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Claudius Regaud
Glioblastoma, Gliosarcoma
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Primary objective To determine maximum tolerated dose \& dose limiting toxicity of imatinib mesylate \& RAD001 when combined w fixed doses of hydroxyurea among pts w recurrent GBM who are on \& not on enzyme-inducing…
- Trial name
- NCT00613132
- Testing
- Gleevec, RAD001, and Hydroxyurea
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Annick Desjardins
Sarcoma, Osteosarcoma
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Background GD2 is a well-characterized tumor antigen in neuroblastoma, which is also expressed on osteosarcomas and some other sarcomas.
- Conditions
- Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
- Trial name
- NCT02107963
- Testing
- Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Pigmented Skin Lesion
Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions
Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths at a 1:28 lifetime incidence (2016).
- Conditions
- Melanoma, Pigmented Skin Lesion, Dysplastic Nevi
- Trial name
- NNCD (NCT03362138)
- Testing
- dermoscopy
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Assuta Hospital Systems
Carcinoid Tumor, Neuroendocrine Tumors
Clinical and Pathologic Studies in Neuroendocrine Tumors
This research involves the study of neuroendocrine tumors in order to better understand how the disease grows and spreads. This study requires will use tissue collected from from biopsies performed during your regular medical…
- Trial name
- NCT00657332
- Testing
- blood sample draw, urine sample
- Sponsor
- Stanford University
Melanoma (Skin Cancer)
Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
The treatment of melanoma has improved significantly in recent years. A modern form of cancer treatment known as immunotherapy with checkpoint inhibitors plays a key role in this.
- Trial name
- Melafit (NCT07680452)
- Testing
- High-Fiber Diet, High-Fiber Diet and Short-Term Fasting
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00045149
- Testing
- aldesleukin, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Astrocytoma, Oligodendroglioma, Adult
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
This clinical trial studies the side effects of temporally-modulated pulsed radiation therapy (TMPRT) in patients with IDH-mutant gliomas who have previously received radiation therapy to the brain.
- Conditions
- Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant
- Trial name
- NCT05393258
- Testing
- temporally-modulated pulsed radiotherapy (TMPRT)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not…
- Conditions
- Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
- Trial name
- NCT00102648
- Testing
- Lonafarnib, Temozolomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Skin Lesion, Melanoma (Skin)
Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)
The goal of the SFI is to provide non-invasive information about tissue remodeling occurring during melanocytic transition and atypia development in the skin
- Conditions
- Skin Lesion, Melanoma (Skin), Mole
- Trial name
- NCT03535077
- Testing
- Diagnostic Test
- Where
- 6 sites in United States
- Volunteers
- 186 people
- Sponsor
- Orlucent, Inc
Uveal Melanoma
Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
1. Rationale Immunotherapy applying ex vivo generated and tumor antigen-loaded dendritic cells (DC) has now successfully been introduced in the clinic.
- Trial name
- NCT00929019
- Testing
- autologous dendritic cells electroporated with mRNA
- Where
- 2 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Radboud University Medical Center
Glioblastoma Multiforme
Safety and Efficacy of Talampanel in Glioblastoma Multiforme
The purpose of this study is to estimate overall survival for adult patients with newly diagnosed glioblastoma multiforme treated with talampanel during radiation therapy with concurrent and adjuvant temozolomide.
- Trial name
- NCT00267592
- Testing
- Talampanel, Radiation Therapy (RT) 5 days a week +, temozolomide(TMZ) 75mg
- Volunteers
- 72 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.